Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest announcement is out from Polarean Imaging ( (GB:POLX) ).
Polarean Imaging has reported a significant increase in its FY24 unaudited revenue, reaching between $3.0 million and $3.1 million, surpassing its revenue guidance. The company has expanded its customer base for the Xenon MRI platform and increased sales of its proprietary Xenon gas blend cylinders by over 50%. A key development is the signing of a distribution agreement with Sumtage in Taiwan, marking Polarean’s first step towards international commercialization. With a strengthened sales team and strategic partnerships, Polarean is well-positioned for further growth in 2025.
More about Polarean Imaging
Polarean Imaging is a medical imaging technology company focused on revolutionizing pulmonary medicine through advanced MRI technology. The company specializes in the development and commercialization of the XENOVIEW MRI platform, which includes a hyperpolarized Xenon MRI contrast agent, gas hyperpolarization system, and associated software and accessories. Polarean aims to address the unmet medical needs of patients with chronic respiratory diseases by providing non-invasive and radiation-free imaging solutions.
YTD Price Performance: 5.00%
Average Trading Volume: 15,725
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $20.63M
For detailed information about POLX stock, go to TipRanks’ Stock Analysis page.